Safety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients

Massari, P.; Duro-Garcia, Valter; Girón, Fernando Fernández; Hernández, Eddy; Juárez, F; Castro, Cleudson; Toledo, Manuel

doi:10.1016/j.transproceed.2004.12.020

Cited by 42 publications

(22 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Since mycophenolate mofetil is known to have gastrointestinal side-effects, enteric-coated mycophenolate sodium was designed to improve gastrointestinal tolerability. 2 We aimed to evaluate the effectiveness of mycophenolate sodium in the treatment of pemphigus vulgaris.…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of long‐term mycophenolate sodium therapy in pemphigus vulgaris

Başkan

Yilmaz

Tunali

et al. 2009

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of long‐term mycophenolate sodium therapy in pemphigus vulgaris

Başkan

Yilmaz

Tunali

et al. 2009

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…10 In contrast, long-term administration of EC-MPS has been reported to be effective and safe in organ transplant patients. 10,14,[17][18][19][20] Some studies have compared the safety of EC-MPS with that of MMF. 19,20 A multicenter, openlabel, prospective study reported that in patients with moderate to severe gastrointestinal symptoms, a change in treatment from MMF to EC-MPS significantly reduces gastrointestinal symptoms and improves the quality of life.…”

Section: Discussionmentioning

confidence: 99%

“…10,14,[17][18][19][20] Some studies have compared the safety of EC-MPS with that of MMF. 19,20 A multicenter, openlabel, prospective study reported that in patients with moderate to severe gastrointestinal symptoms, a change in treatment from MMF to EC-MPS significantly reduces gastrointestinal symptoms and improves the quality of life. 10 Another randomized multicenter trial reported the effect of conversion from MMF to EC-MPS on the maximum tolerated dose and gastrointestinal symptoms after kidney transplantation.…”

Section: Discussionmentioning

confidence: 99%

Enteric-coated Mycophenolate Sodium as a Corticosteroid-sparing Agent for the Treatment of Autoimmune Scleritis

Hwang

Chen

et al. 2011

Cornea

View full text Add to dashboard Cite

show abstract

“…It was developed, in part, as an attempt to reduce gastrointestinal side effects compared with MMF, although it remains controversial whether this has been achieved [35].…”

Section: Mycophenolic Acid Delayed Releasementioning

confidence: 99%

Immunosuppression Therapy for Pediatric Heart Transplantation

Irving

Webber

2010

Curr Treat Options Cardio Med

View full text Add to dashboard Cite

Outcomes following cardiac transplantation in childhood continue to improve. Advances in immunosuppressive therapy over the past two decades likely have contributed to this trend. The evolution in the management of immunosuppression in children has been based on clinical experience rather than on evidence-based medicine; indeed, there have been no pivotal randomized controlled trials of any form of immunosuppression in pediatric thoracic transplantation. Important trends in immunosuppressive therapy and transplant outcomes have been obtained from large transplant registries. Several trends have been identified since the last review of this topic in this journal. First, there is increased knowledge of the pharmacodynamics and pharmacokinetics of immunosuppressive drugs in children, with notable advances in the field of pharmacogenomics. These studies help explain individual variations in drug exposure, efficacy, and adverse events. They also help explain racial and ethnic variations in drug metabolism and efficacy. Second, there have been clear trends in the use of specific immunosuppressive medications. Use of induction therapy, especially polyclonal T cell-depleting antibody preparations, has increased significantly in recent years. The calcineurin inhibitor (CNI) tacrolimus is being used as the cornerstone of maintenance therapy in lieu of cyclosporine in more and more centers. Mounting evidence suggests that use of adjunctive agents (notably mycophenolate mofetil [MMF]) may improve outcomes, including survival, suggesting that monotherapy with CNIs is not the ideal maintenance therapy. Despite its increased cost, MMF has largely replaced azathioprine as the adjunctive agent of choice. Inhibitors of the mammalian target of rapamycin (i.e., sirolimus and everolimus) have not yet assumed a major place as adjunctive agents, as their safety and efficacy have not been well established in children. With the improvements in immunosuppressive therapy, the justification for routine corticosteroid use is far from clear, and many centers have shown excellent outcomes with complete steroid avoidance. Third, there is increasing interest in the importance of anti-HLA antibodies as important risk factors for adverse graft and patient outcomes. This is generating intense interest in treatments that target B cells and plasma cells. Finally, there is increasing realization that the "one size fits all" approach to immunosuppressive therapy is an obsolete concept and that the ultimate goal is to tailor immunosuppressive therapy to the needs of the individual patient. The development of reliable biomarkers of the patient's immune response to the allograft will be essential for optimal individualized immunosuppressive management.

show abstract

Safety Assessment of the Conversion From Mycophenolate Mofetil to Enteric-Coated Mycophenolate Sodium in Stable Renal Transplant Recipients

Cited by 42 publications

References 10 publications

Efficacy and safety of long‐term mycophenolate sodium therapy in pemphigus vulgaris

Efficacy and safety of long‐term mycophenolate sodium therapy in pemphigus vulgaris

Enteric-coated Mycophenolate Sodium as a Corticosteroid-sparing Agent for the Treatment of Autoimmune Scleritis

Immunosuppression Therapy for Pediatric Heart Transplantation

Contact Info

Product

Resources

About